IE 6-Month Mortality Risk Score (ICE)
Predicts 6-month mortality in definite infective endocarditis from host factors, IE characteristics, complications and surgical treatment (International Collaboration on Endocarditis).
Score interpretation
Lowest risk quintile: 6-month mortality 10.3 % (ICE-PLUS validation).
→ Standard IE management with the endocarditis team.
6-month mortality 17.0 % (ICE-PLUS validation).
→ Endocarditis team review; reassess complications and surgical indications.
6-month mortality 25.5 % (ICE-PLUS validation).
→ Endocarditis team review; reassess complications and surgical indications.
6-month mortality 37.8 % (ICE-PLUS validation).
→ High risk: urgent endocarditis team and cardiac surgical review.
Highest risk quintile: 6-month mortality 52.9 % (ICE-PLUS validation).
→ Very high risk: urgent endocarditis team and cardiac surgical review; discuss goals of care.
Interpretation bands for the IE Mortality. Apply clinical judgement and local guidance.
References
- Park LP, et al. Validated risk score for predicting 6-month mortality in infective endocarditis. J Am Heart Assoc. 2016;5(4):e003016.
Related
Curated clinical cross-links plus same-class fallbacks.
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.